Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee

Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee

Source: 
Motley Fool
snippet: 

Things aren't looking great for oxycodegol, a potential new pain drug that has been in Nektar Therapeutics' (NASDAQ: NKTR) late-stage pipeline for a long time. The FDA will discuss the slow-acting opioid's benefits in light of its risks with a panel of independent experts on Jan. 14, 2020, and recently released briefing documents prepared for the advisory committee aren't too encouraging.